DMT-310 is under clinical development by Dermata Therapeutics and currently in Phase I for Psoriasis. According to GlobalData, Phase I drugs for Psoriasis have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how DMT-310’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DMT-310 overview
DMT-310 is under development for the treatment of acne vulgaris, psoriasis and it was under development for the treatment of papulopustular rosacea. The drug candidate is a variant of sponge administered topically. It is developed based on the Spongilla platform technology.
Dermata Therapeutics overview
Dermata Therapeutics is a biotechnology company. It discovers, develops and commercializes treatments for medical and aesthetic skin conditions. The company is investigating its lead product candidate DMT310, a natural source of spongilla lacustris with multiple active components to treat inflammatory skin diseases including acne, psoriasis and rosacea. It is also evaluating DMT400, a combination regimen of biologic molecules against various skin diseases and cosmetic applications; and DMT410 drug developed in combination with botulinum toxin for the treatment of hyperhidrosis and aesthetics. The company utilizes its proprietary Spongilla platform technology to develop its products. Dermata Therapeutics is headquartered in San Diego, California, the US.
For a complete picture of DMT-310’s drug-specific PTSR and LoA scores, buy the report here.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.
